Although the median survival rate for patients with metastatic colorectal cancer has doubled over the past decade, it remains only about 24 months

The DF/HCC Skin SPORE, led by Thomas Kupper, MD (BWH), has been highly successful in creating cohesion in the Cutaneous Oncology and Melanoma program, sparking new collaborative grants, fostering innovative ideas in cancer research, and advancing the careers of junior investigators

The NIH continues to recognize DF/HCC as a leader in cancer research by awarding funding to a number of our research initiatives

Even though prostate cancer is the second leading cause of cancer death in men in the United States, some patients may wonder whether treatment is worse than the disease

Few clinicians understand the consequences of prostate cancer treatment better than urological surgeon-scientist Martin Sanda, MD, director of the multidisciplinary prostate cancer clinic at BIDMC

Glioblastoma, the most common and lethal type of malignant brain tumor, has a poor prognosis and very few chemotherapeutic options